Zachary C. Fogarty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zachary C. Fogarty has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Chen Wang
Mayo Clinic
23 shared publications - Jun Jiang
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
18 shared publications - Anastasios Dimou
Department of Oncology, Mayo Clinic, Rochester, MN
17 shared publications - Hongfang Liu
Department of Quantitative and Systems Health Sciences, University of Texas at Austin Dell Medical School, Austin, TX 78712, USA
17 shared publications - William Bruce Wong
Genentech, Inc., South San Francisco, CA
17 shared publications - Yiqing Zhao
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States
17 shared publications
Latest Publications
- 20 January 2026
- Published by Oxford University Press (OUP) in Biostatistics
- Vol. 27 (1)
Scalable inference for spatial generalized mixed models for use in multiplexed imaging analysis
Summary: Understanding how cells interact to coordinate tissue function and respond to disease remains a central challenge in biology. Recently developed multiplex bioimaging technologies [multiplex immunofluorescence (MxIF)] can quantify multiple protein markers at a single-cell resolution in spatially preserved tissue, offering the opportunity to understand how cellular organization relates to disease mechanisms and treatment response. Spatial generalized linear mixed models for cell co-localization offer a flexible framework for these analyses, accommodating cell-, image-, or subject-level predictors while accounting for correlation arising from repeated cells per image, repeated images per subject, and spatial dependence among nearby cells. However, as MxIF data typically have hundreds of thousands to millions of cells per study, fitting the full spatial model is computationally infeasible due to the large, dense, spatial covariance matrix. We present a scalable inference strategy that uses parallelizable eigen-decomposition of an empirically estimated spatial correlation matrix to approximate the full spatial model. This approach enables fast estimation of fixed effects of interest without requiring formal estimation of spatial parameters or surface prediction. In simulations, our proposed method could be fitted to large datasets ($ \sim $ 285,000 observations) in under a minute, with runtime linearly increasing by only $ \sim $ 7 s per 50,000 additional observations. This scalability makes cell-level modeling in the presence of spatial correlation feasible for real-world MxIF datasets, as we demonstrate through applications to metastatic melanoma and high-grade serous ovarian carcinoma.- 20 January 2026
- Published by Oxford University Press (OUP) in Biostatistics
- Vol. 27 (1)
Scalable inference for spatial generalized mixed models for use in multiplexed imaging analysis
Summary: Understanding how cells interact to coordinate tissue function and respond to disease remains a central challenge in biology. Recently developed multiplex bioimaging technologies [multiplex immunofluorescence (MxIF)] can quantify multiple protein markers at a single-cell resolution in spatially preserved tissue, offering the opportunity to understand how cellular organization relates to disease mechanisms and treatment response. Spatial generalized linear mixed models for cell co-localization offer a flexible framework for these analyses, accommodating cell-, image-, or subject-level predictors while accounting for correlation arising from repeated cells per image, repeated images per subject, and spatial dependence among nearby cells. However, as MxIF data typically have hundreds of thousands to millions of cells per study, fitting the full spatial model is computationally infeasible due to the large, dense, spatial covariance matrix. We present a scalable inference strategy that uses parallelizable eigen-decomposition of an empirically estimated spatial correlation matrix to approximate the full spatial model. This approach enables fast estimation of fixed effects of interest without requiring formal estimation of spatial parameters or surface prediction. In simulations, our proposed method could be fitted to large datasets ($ \sim $ 285,000 observations) in under a minute, with runtime linearly increasing by only $ \sim $ 7 s per 50,000 additional observations. This scalability makes cell-level modeling in the presence of spatial correlation feasible for real-world MxIF datasets, as we demonstrate through applications to metastatic melanoma and high-grade serous ovarian carcinoma.- Open Access
- 6 January 2025
- Published by Springer Nature in Research Square
Towards H&E Referenced Multiplex Immunofluorescence Interpretation: Spatial Co-localization, Cell Feature Validation, and Virtual H&E Generation
Multiplexed Immunofluorescence (MxIF) enables detailed immune cell phenotyping, providing critical insights into cell behavior within the tumor immune microenvironment (TIME). However, signal integrity can be compromised due to the complex cyclic staining processes inherent to MxIF. Hematoxylin and Eosin (H&E) staining, on the other hand, offers complementary information through its depiction of cell morphology and texture patterns and is often visually cross-referenced with MxIF in clinical settings. In this study, we proposed a novel framework to align H&E and MxIF images for precise cross-modal cell feature validation. Using cell detection outputs from each modality as anchors, we formulated the multimodal image registration problem as point set alignment. Coherent Point Drift (CPD) is employed for initial alignment, followed by Graph Matching (GM) for refinement. Evaluations on ovarian cancer tissue microarrays (TMAs) demonstrate that our method achieves high alignment accuracy, enabling reliable validation of cell-level features across modalities for both restained and serial sections. Our results indicate that restained H&E enhances confidence in findings derived from MxIF. Additionally, we demonstrated the feasibility of generating high-quality virtual H&E images from MxIF data when restained H&E is unavailable, offering a viable alternative for integrated multimodal analysis.
- 6 January 2025
- Published by Springer Nature in Research Square
Open AccessTowards H&E Referenced Multiplex Immunofluorescence Interpretation: Spatial Co-localization, Cell Feature Validation, and Virtual H&E Generation
Multiplexed Immunofluorescence (MxIF) enables detailed immune cell phenotyping, providing critical insights into cell behavior within the tumor immune microenvironment (TIME). However, signal integrity can be compromised due to the complex cyclic staining processes inherent to MxIF. Hematoxylin and Eosin (H&E) staining, on the other hand, offers complementary information through its depiction of cell morphology and texture patterns and is often visually cross-referenced with MxIF in clinical settings. In this study, we proposed a novel framework to align H&E and MxIF images for precise cross-modal cell feature validation. Using cell detection outputs from each modality as anchors, we formulated the multimodal image registration problem as point set alignment. Coherent Point Drift (CPD) is employed for initial alignment, followed by Graph Matching (GM) for refinement. Evaluations on ovarian cancer tissue microarrays (TMAs) demonstrate that our method achieves high alignment accuracy, enabling reliable validation of cell-level features across modalities for both restained and serial sections. Our results indicate that restained H&E enhances confidence in findings derived from MxIF. Additionally, we demonstrated the feasibility of generating high-quality virtual H&E images from MxIF data when restained H&E is unavailable, offering a viable alternative for integrated multimodal analysis.
- Open Access
- 18 March 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (6) , 101068
Metabolome-wide association identifies altered metabolites and metabolic pathways in the serum of patients with cholangiocarcinoma
- 18 March 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (6) , 101068
Open AccessMetabolome-wide association identifies altered metabolites and metabolic pathways in the serum of patients with cholangiocarcinoma
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Data from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Advances in genetic technology have led to the increasing use of genomic panels in precision oncology practice, with panels ranging from a couple to hundreds of genes. However, the clinical utilization and utility of oncology genomic panels, especially among vulnerable populations, is unclear. We examined the association of panel size with socioeconomic status and clinical trial matching. We retrospectively identified 9,886 eligible adult subjects in the Mayo Clinic Health System who underwent genomic testing between January 1, 2016 and June 30, 2020. Patient data were retrieved from structured and unstructured data sources of institutional collections, including cancer registries, clinical data warehouses, and clinical notes. Socioeconomic surrogates were approximated using the Area Deprivation Index (ADI) corresponding to primary residence addresses. Logistic regression was performed to analyze relationships between ADI or rural/urban status and (i) use of genomic test by panel size; (ii) clinical trial matching status. Compared with patients from the most affluent areas, patients had a lower odds of receiving a panel test (vs. a single-gene test) if from areas of higher socioeconomic deprivation [OR (95% confidence interval (CI): 0.71 (0.61–0.83), P < 0.01] or a rural area [OR (95% CI): 0.85 (0.76–0.96), P < 0.01]. Patients in areas of higher socioeconomic deprivation were less likely to be matched to clinical trials if receiving medium panel tests [(OR) (95% CI): 0.69 (0.49–0.97), P = 0.03]; however, there was no difference among patients receiving large panel tests (P > 0.05) and rural patients were almost 2x greater odds of being matched if receiving a large panel test [(OR) (95% CI): 1.76 (1.21–2.55), P < 0.01].Significance:We identified socioeconomic and rurality disparities in the use of genomic tests and trial matching by panel size, which may have implications for equal access to targeted therapies. The lack of association between large panel tests and clinical trial matching by socioeconomic status, suggests a potential health equity impact, while removing barriers in access to large panels for rural patients may improve access to trials. However, further research is needed.
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Advances in genetic technology have led to the increasing use of genomic panels in precision oncology practice, with panels ranging from a couple to hundreds of genes. However, the clinical utilization and utility of oncology genomic panels, especially among vulnerable populations, is unclear. We examined the association of panel size with socioeconomic status and clinical trial matching. We retrospectively identified 9,886 eligible adult subjects in the Mayo Clinic Health System who underwent genomic testing between January 1, 2016 and June 30, 2020. Patient data were retrieved from structured and unstructured data sources of institutional collections, including cancer registries, clinical data warehouses, and clinical notes. Socioeconomic surrogates were approximated using the Area Deprivation Index (ADI) corresponding to primary residence addresses. Logistic regression was performed to analyze relationships between ADI or rural/urban status and (i) use of genomic test by panel size; (ii) clinical trial matching status. Compared with patients from the most affluent areas, patients had a lower odds of receiving a panel test (vs. a single-gene test) if from areas of higher socioeconomic deprivation [OR (95% confidence interval (CI): 0.71 (0.61–0.83), P < 0.01] or a rural area [OR (95% CI): 0.85 (0.76–0.96), P < 0.01]. Patients in areas of higher socioeconomic deprivation were less likely to be matched to clinical trials if receiving medium panel tests [(OR) (95% CI): 0.69 (0.49–0.97), P = 0.03]; however, there was no difference among patients receiving large panel tests (P > 0.05) and rural patients were almost 2x greater odds of being matched if receiving a large panel test [(OR) (95% CI): 1.76 (1.21–2.55), P < 0.01].Significance:We identified socioeconomic and rurality disparities in the use of genomic tests and trial matching by panel size, which may have implications for equal access to targeted therapies. The lack of association between large panel tests and clinical trial matching by socioeconomic status, suggests a potential health equity impact, while removing barriers in access to large panels for rural patients may improve access to trials. However, further research is needed.
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
TABLE 2 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Time to test return (turnaround time) for large panel, medium panel, and single-gene genomic tests
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Time to test return (turnaround time) for large panel, medium panel, and single-gene genomic tests
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Trends of single-gene, medium, large genomic test panel distribution among patients with lung cancer and non-lung cancer. A, Proportion and total number of genetic tests over time by size [large panel (50+ genes), medium panel (2 to 49 genes), single-gene] among patients with a lung cancer diagnosis. B, Proportion and total number of genetic tests over time by size [large panel (50+ genes), medium panel (2 to 49 genes), single-gene] among patients with a non-lung cancer diagnosis.
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Trends of single-gene, medium, large genomic test panel distribution among patients with lung cancer and non-lung cancer. A, Proportion and total number of genetic tests over time by size [large panel (50+ genes), medium panel (2 to 49 genes), single-gene] among patients with a lung cancer diagnosis. B, Proportion and total number of genetic tests over time by size [large panel (50+ genes), medium panel (2 to 49 genes), single-gene] among patients with a non-lung cancer diagnosis.
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
TABLE 3 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Association of panel size with ADI and urban/rural statusa
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 3 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Association of panel size with ADI and urban/rural statusa
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Demographic characteristics of patients
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Demographic characteristics of patients
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Supplemental Table S1 shows the association of area level deprivation and rurality with genomic test type in the subgroup of patients with known stage of disease
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Supplemental Table S1 shows the association of area level deprivation and rurality with genomic test type in the subgroup of patients with known stage of disease
- Open Access
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Demographic characteristics of patients
- 5 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Demographic characteristics of patients